Baker Bros. Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Baker Bros. Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$587M	Hold	1,753,198	–	–	2.94%	11
2026 Q1	$565M	Buy	1,753,198 +626,710	+56%	+$194M	3.24%	11
2025 Q4	$332M	Buy	1,126,488 +437,000	+63%	+$81.4M	1.94%	12
2025 Q3	$36.5M	Hold	689,488	–	–	0.26%	36
2025 Q2	$29M	Buy	689,488 +357,955	+108%	+$13.6M	0.28%	32
2025 Q1	$12.6M	Hold	331,533	–	–	0.14%	41
2024 Q4	$25.5M	Buy	331,533 +8,428	+3%	+$610K	0.27%	40
2024 Q3	$18.6M	Buy	323,105 +191,572	+146%	+$10.3M	0.19%	44
2024 Q2	$5.44M	Hold	131,533	–	–	0.07%	62
2024 Q1	$8.03M	Hold	131,533	–	–	0.1%	55
2023 Q4	$2.93M	Buy	131,533 +6,205	+5%	+$112K	0.03%	68
2023 Q3	$3.21M	Hold	125,328	–	–	0.02%	74
2023 Q2	$2.16M	Hold	125,328	–	–	0.01%	93
2023 Q1	$1.52M	Buy	125,328 +3,307	+3%	+$140K	0.01%	95
2022 Q4	$4.36M	Buy	+122,021	New	+$3.81M	0.03%	80

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Baker Bros. Advisors's PRAX Position: Q2 2026 in Review

Baker Bros. Advisors held its Praxis Precision Medicines (PRAX) position steady in Q2 2026 at 1,753,198 shares worth $587M. The position accounts for 2.94% of the portfolio, ranked #11.

Baker Bros. Advisors first reported a position in PRAX in Q4 2022 and has held it in 15 quarters since. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Baker Bros. Advisors held 1,753,198 shares of Praxis Precision Medicines worth $587M as of Q2 2026.
Baker Bros. Advisors left its Praxis Precision Medicines share count unchanged in Q2 2026.
Praxis Precision Medicines made up 2.94% of Baker Bros. Advisors's portfolio in Q2 2026, its #11 holding.
Baker Bros. Advisors first reported a position in Praxis Precision Medicines in Q4 2022 and has held it in 15 quarters since.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.